<![CDATA[Telangiectasis]]> https://www.eurekaselect.com RSS Feed for Disease Wise Article | BenthamScience EurekaSelect (+http://eurekaselect.com) Fri, 29 Mar 2024 14:24:46 +0000 <![CDATA[Telangiectasis]]> https://www.eurekaselect.com https://www.eurekaselect.com <![CDATA[Molecular Modeling of Sulfonylmorpholinopyrimidines as the Ataxia Telangiectasis Mutated and RAD3-related (ATR) Protein Kinase Inhibitors by Computational Explorations]]>https://www.eurekaselect.comarticle/692022 = 0.550; r2 = 0.978; standard error of estimate [SEE] = 0.129; F = 177.729 and r2pred = 0.530) and the CoMSIA model (q2 = 0.632; r2 = 0.991; standard error of estimate [SEE] = 0.088; F = 277.224 and r2 pred = 0.322) are acceptable. The 3D-model of ATR kinase was further assessed by ERRAT, WHATCHECK and PROCHECK, which showed that the final model is reliable with 78.9% of the residues in the most favored regions. According to molecular docking, Ala562, Ser563, Leu564 and Lys585 were the vital amino acid residues to the ATR kinase. This article can support useful information for designing novel and high bioactive ATR kinase inhibitors.]]> <![CDATA[Patent Selections:]]>https://www.eurekaselect.comarticle/65710 <![CDATA[Skin Cancers in Elderly Patients ]]>https://www.eurekaselect.comarticle/56669

The anti-tumor immune response is also mediated by the cytotoxic T- lymphocytes and in the elderly a strong reduction of T-cell function has been demonstrated. In elderly patients the diagnosis and the treatment of skin cancers can be different from younger counterpart. For example in older patients with melanoma is important to evaluate Breslow depth while higher mitotic rate has major value in younger patients. Moreover, the treatment should consider the performance status of patients and their compliance. ]]> <![CDATA[Matrix Metalloproteinases as Potential Targets in the Venous Dilation Associated with Varicose Veins]]>https://www.eurekaselect.comarticle/48844 <![CDATA[Biomarkers to Assess the Targeting of DNA Repair Pathways to Augment Tumor Response to Therapy]]>https://www.eurekaselect.comarticle/43363 <![CDATA[ Treatment of Recurrent Epistaxis in HHT]]>https://www.eurekaselect.comarticle/997 <![CDATA[ Treatment of Choroidal Neovascularization in High Myopia]]>https://www.eurekaselect.comarticle/16433 <![CDATA[ Editorial [Hot Topic: Targeting Mast Cells and Basophils in Allergy and Beyond: Emerging Concepts (Executive Guest Editor: Petr Heneberg)]]]>https://www.eurekaselect.comarticle/20767 <![CDATA[ Mast Cells as Targets of Pimecrolimus]]>https://www.eurekaselect.comarticle/20777 <![CDATA[ Arthropathy in Patients with CREST Variant Scleroderma]]>https://www.eurekaselect.comarticle/22150 <![CDATA[ Medical Treatment of Chronic Venous Insufficiency]]>https://www.eurekaselect.comarticle/23156 <![CDATA[ Micronized Purified Flavonoid Fraction (MPFF)*: A Review of its Pharmacological Effects, Therapeutic Efficacy and Benefits in the Management of Chronic Venous Insufficiency]]>https://www.eurekaselect.comarticle/25002 <![CDATA[ Clinical Value of Prostacyclin and its Analogs in the Management of Pulmonary Arterial Hypertension]]>https://www.eurekaselect.comarticle/25986 <![CDATA[ Ophthalmological and Otological Manifestations in the Antiphospholipid Syndrome]]>https://www.eurekaselect.comarticle/30866 <![CDATA[ Systemic Sclerosis: Clinical Manifestations]]>https://www.eurekaselect.comarticle/31814